MIRA

$1.17

Pre-MarketAs of Mar 17, 8:00 PM UTC

MIRA Pharmaceuticals, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.17
Potential Upside
5%
Whystock Fair Value$1.23
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers - General

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican righ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$49.00M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.80
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-123.33%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
89.79

Recent News

Market Exclusive
Feb 8, 2026

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Aurora Cannabis Announced Refocused Strategy as Global Medical Sales Hit Record High in 2026 Third Quarter Canopy Growth Reported Mixed Results in its Fiscal Third Quarter of 2026 Cronos Group Launched Premium Lord Jones Brand in Israel in Global Expansion Push Key Takeaways; Psychedelic Sector Clearmind Announced the Inclusion of its […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MT Newswires
Oct 16, 2025

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks fell late Thursday afternoon with the NYSE Health Care Index down 0.2% and the He

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MT Newswires
Jul 3, 2025

Top Premarket Gainers

FiEE (MINM) shares were up 37% in recent Thursday premarket activity, after the company said Wednesd

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Benzinga
Jun 30, 2025

EXCLUSIVE: MIRA Pharmaceuticals' Soon To Be Acquired Weight Loss Drug Reverses Obesity Markers And Cuts Nicotine Craving In Animal Study

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) on Monday revealed new animal study results from SKNY-1, a next-generation oral therapeutic. The company says the findings further support the advancement of SKNY-1 toward Investigational New Drug (IND) enabling studies. With obesity and smoking representing two of the leading causes of preventable death and a combined global market opportunity exceeding $200 billion, MIRA intends to prioritize SKNY-1 as a potential cornerstone asset pending the completio

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
TipRanks
May 9, 2025

Psychedelic: Compass, GH Research, MindMed report quarterly earnings

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a patent grant and study results. Q1 EARNINGS: On Thursday, Compass Pathways (CMPS) reported a first quarter loss per share of (24c), which compared to analyst estimates of a loss per share of (49c). The company said cash and cash equivalents were $260.1M as of March 31, compared with $165.1M as of December 31. Compass also guided to full year 2025 net cash used in operatin

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.